Evome Medical Technologies Inc.
LNDZF
$0.0112
-$0.0488-81.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -19.93% | 13.32% | 44.37% | 46.33% | 55.96% |
| Total Revenue | -19.93% | 13.32% | 44.37% | 46.33% | 55.96% |
| Cost of Revenue | -17.99% | 13.74% | 49.82% | 49.11% | 76.85% |
| Gross Profit | -7.93% | -18.75% | -149.61% | -116.71% | -326.30% |
| SG&A Expenses | -- | -- | -- | -- | -- |
| Depreciation & Amortization | -5.72% | 22.09% | 67.57% | 102.04% | 137.63% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.21% | 14.26% | 50.85% | 51.74% | 71.30% |
| Operating Income | -1.21% | -20.28% | -105.01% | -108.35% | -409.94% |
| Income Before Tax | -182.89% | 10.65% | 25.49% | 34.13% | 49.90% |
| Income Tax Expenses | 100.59% | 100.85% | 100.58% | 101.52% | -1,435.76% |
| Earnings from Continuing Operations | -389.35% | -7.27% | 12.43% | 21.25% | 70.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -389.35% | -7.27% | 12.43% | 21.25% | 70.61% |
| EBIT | -- | -- | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -226.32% | 24.95% | 38.73% | 42.88% | 71.60% |
| Normalized Basic EPS | 19.08% | 36.71% | 18.73% | 29.01% | -20.78% |
| EPS Diluted | -226.32% | 25.17% | 38.89% | 43.04% | 71.69% |
| Normalized Diluted EPS | 19.08% | 36.71% | 18.73% | 29.01% | -20.78% |
| Average Basic Shares Outstanding | 29.30% | 36.17% | 35.23% | 32.05% | 32.88% |
| Average Diluted Shares Outstanding | 29.30% | 36.17% | 35.23% | 32.05% | 32.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
